DT Pre Market Jan 13 2017, page-16

SPL

Massive earnings potential for Vivagel.

At least 100m USD/annum , very conservatively, more likely double that.

Only drug in a billion USD market.

This gives 7 bucks per share based upon Vivagel alone.

The DEP platform is the main game;

DEP docetaxel trial almost finished. Chemo drug without hair loss or neutropenia.
Multi billion dollar market.

Astrazenica has licensed a couple of candidates. 100s of millions in milestone payments and 15 percent royalties for each drug.

Many other strings to their bow.

Sounds retarded, but could see a 50 dollar SP in the future.

Should be a good day trade. Over 6m outstanding shorts. Make em piss...

Cheers